Regulatory B cells (Bregs) suppress and reduce autoimmune pathology. However, given the variety of Breg subsets, the role of Bregs in the pathogenesis of type 1 diabetes is still unclear. Here, we dissect this fundamental mechanism. We show that natural protection from type 1 diabetes in nonobese diabetic (NOD) mice is associated with increased numbers of IL-10-producing B cells, while development of type 1 diabetes in NOD mice occurs in animals with compromised IL-10 production by B cells. However, B cells from diabetic mice regain IL-10 function if activated by the innate immune receptor TLR4 and can suppress insulin-specific CD8 T cells in a dendritic cell (DC)-dependent, IL-10-mediated fashion. Suppression of CD8 T cells is reliant on B-cell contact with DCs. This cell contact results in deactivation of DCs, inducing a tolerogenic state, which in turn can regulate pathogenic CD8 T cells. Our findings emphasize the importance of DC-Breg interactions during the development of type 1 diabetes.
Regulatory B cells (Bregs) suppress immune responses and support immune tolerance. Breg cells mitigate inflammation via the production of cytokines such as IL-10, TGFβ and IL-35, [1] [2] [3] which modulate the response of pathogenic T cells and aid in the generation of other regulatory lymphocyte populations. Bregs can suppress various autoimmune diseases, including models of experimental autoimmune encephalomyelitis (EAE) and arthritis. [4] [5] [6] However, in type 1 diabetes, a dual role for B cells is evident. B cells play a pathological role, as B-cell depletion delays disease onset and protects against diabetes. [7] [8] [9] Conversely, Bregs can prevent the onset of disease in a NOD mouse model. 2, 10 B cells stimulated with lipopolysaccharide (LPS) upregulate FasL expression, increase TGFβ secretion, and prevent the onset of diabetes upon adoptive transfer. 2 Furthermore, LPS-stimulated B cells induce CD8 T-cell anergy in a membrane-bound TGFβ-dependent manner. 11 Activation of B cells through the B-cell receptor (BCR) can also mediate protection from diabetes in NOD mice via an IL-10-dependent mechanism. 12 In patients with type 1 diabetes, IL-10-producing B-cell numbers are diminished in the peripheral blood compared with healthy control individuals and autoantibody-positive relatives. 13 Similar to humans, NOD mice spontaneously develop type 1 diabetes. However, in most, if not all, NOD mouse colonies worldwide,~20% (or more) of the NOD mice remain normoglycemic and "protected" from diabetes despite their genetic predisposition. 14 However, few studies have been performed to uncover the mechanism underlying this natural protection. It is suggested that B cells, specifically anergic CD40 + IL-10-producing B cells found in the pancreatic islets of long-term normoglycemic (protected) mice, 13 may confer this natural protection. However, given the heterogeneity among regulatory B cells, 15 which can be induced via stimulation with either TLR agonists or an anti-CD40 antibody, we suggest that the mechanism by which B cells induce natural protection still remains undefined.
Here, we report that B cells from NOD mice that have developed diabetes have lost the capacity to produce IL-10, whereas B cells from naturally protected NOD animals have an enhanced frequency of IL-10-producing B cells, regardless of the mode of B-cell activation. However, if B cells from diabetic NOD mice receive signaling through the innate immune receptor TLR4, they regain the IL-10-producing function and are able to suppress insulin-specific CD8 T cells. For B cells to exert this suppression, contact with dendritic cells (DCs) is required and is mediated via IL-10. Direct B-cell-DC interaction deactivates mature conventional DCs and promotes an IL-10-dependent tolerogenic DC population.
RESULTS

Altered B-cell functions in NOD mice with type 1 diabetes
To determine the features of B cells in NOD mice that are "naturally protected" (have not developed diabetes by 30 weeks of age and hereafter referred to as protected, as these mice rarely develop diabetes after 30 weeks), we compared B-cell responses with various stimuli between protected and diabetic NOD mice. B cells were stimulated through adaptive immune costimulatory pathways (anti-CD40 or B CD40 ) and through innate immune pathways by microbial products (LPS-B LPS or CpG-B CPG ). [16] [17] [18] Unstimulated B cells (B US ) were used as controls ( Fig. 1 ). All stimuli upregulated the expression of B-cell activation markers, although the upregulation of MHC I and II expression was not statistically different from the expression in B US . Key differences in surface markers, between the B cells from protected NOD mice and those from diabetic NOD mice, were that the splenic B cells isolated from protected NOD mice had lower expression of MHC I and a significantly lower frequency of CD86-expressing B cells, compared with the splenic B cells from diabetic mice (Fig. 1a ). In B cells from both protected and diabetic NOD mice, the upregulation of CD80 expression was evident, particularly after anti-CD40 stimulation, compared with B US (p < 0.001), whereas we observed and secreted (bottom) IL-6. Cytokines in supernatants were measured by MSD. The black line represents the median value. B cells were gated on live CD19 + cells. Data represent at least four independent experiments. ns nonsignificant, + P < 0.05, ++ P < 0.01, and +++ P < 0.001 versus B US (two-way ANOVA). * P < 0.05, ** P < 0.01, and *** P < 0.001, protected versus diabetic (two-way ANOVA) that the upregulation of CD86 expression was greatest if the cells were stimulated by LPS (p < 0.001). Interestingly, the innate immune stimuli LPS (TLR4) and CPG (TLR9) resulted in increased upregulation of PD-L1 expression on B cells (p < 0.05 and p < 0.001, respectively) compared with B US . We observed that after stimulation with anti-CD40 (B CD40 ), a classic B-cell stimulator that functions via an adaptive immune pathway, PD-L1 expression was similar between the stimulated B cells and unstimulated control cells ( Fig. 1a ). However, no difference in PD-L1 expression was found between protected and diabetic NOD mice, corroborating previous literature. 19 Next, we determined the cytokine production by B cells activated by the different types of stimuli. First, intracytoplasmic staining revealed significant induction of IL-10 in splenic B cells from both protected and diabetic NOD mice compared with B US following activation with the innate immune stimuli LPS and CPG (p < 0.05), but not following stimulation with anti-CD40, the adaptive immune stimulator (Fig. 1b, c ). However, a much higher proportion of B cells from protected NOD mice compared with diabetic NOD mice expressed intracellular IL-10, even without stimulation (B US ) ex vivo ( Fig. 1c , top graph). In particular, there were considerably lower proportions of IL-10-expressing B cells from diabetic NOD mice upon stimulation with anti-CD40 ( Fig. 1c ; top graph). B cell secretion of IL-10 was only observed with LPS and CPG stimulation, but not with anti-CD40 stimulation (Fig. 1c ; bottom graph), corroborating previous literature. 16 Surprisingly, B cells from diabetic NOD mice secreted significantly more IL-10, although only when stimulated with CPG, compared with B cells from protected NOD animals (Fig. 1c , bottom graph; p < 0.01). IL-10 secretion by LPS-stimulated B cells was modestly increased in diabetic NOD mice compared with protected NOD mice, although this difference was not statistically significant (ns). To address whether the greater proportion of IL-10-producing B cells in protected mice was age related, we investigated B6 g7 congenic mice, which have the same MHC haplotype but are not prone to diabetes, to overcome the technical challenge of there being no NOD mice that develop diabetes beyond 30 weeks of age ( Supplementary Fig. 1 ). B6 g7 mice aged >35 weeks old exhibited little IL-10 production, indicating that the potential for IL-10 production was unlikely to be age associated.
Only CPG stimulation induced IL-6-producing B cells from both protected and diabetic mice (Fig. 1d ), and no significant difference was observed between the protected and diabetic NOD mice for either intracytoplasmic or secreted IL-6 ( Fig. 1d ), indicating that diabetes protection was not related to a lack of proinflammatory cytokines in B cells.
These data demonstrated that B cells from diabetic NOD mice were more activated than those from mice protected from diabetes, particularly in regard to CD86 expression ( Fig. 1a , fourth row). Furthermore, B cells from diabetic mice showed a loss of overall intracellular IL-10 production, but could regain this function if stimulated with TLR4 or TLR9, as highlighted by the IL-10 secretion results. Strikingly, when B cells were stimulated with anti-CD40, only protected mice had the potential to produce cytoplasmic IL-10.
LPS-stimulated B cells suppress antigen-specific CD8 T cells in the presence of DCs
We next investigated whether B cells from diabetic or protected NOD mice could regulate antigen-specific CD8 T cells via both innate and adaptive immune signaling. B cells were cocultured with insulin-specific CD8 T cells from TCR transgenic G9Cα -/mice 20 in the presence of BM-DCs from NOD.PI2tg mice, which express proinsulin (driven by the MHC class II promoter) in antigen-presenting cells (experimental scheme shown in Fig. 2a ). This culture system allowed intrinsic antigen-specific presentation, by proinsulin-expressing DCs to insulin-specific CD8 T cells, without exogenous antigen. Considering that NOD.PI2tg DCs express proinsulin, they should be targeted by CD8 T cells from G9Cα -/mice. Indeed, DC viability was significantly diminished in control CD8 and DC cultures (without B cells) ( Fig. 2b ). The addition of B cells prevented the killing of DCs by CD8 T cells (Fig. 2b) , and importantly, stimulated B cells (B LPS , B CD40 and B CPG ) promoted enhanced DC survival compared with unstimulated B cells (B US ) ( Fig. 2b ). Next, we examined the proliferative function of CD8 T cells in response to the intrinsic antigen presented by DCs in a CFSE dilution assay, in the presence of stimulated or unstimulated B cells, from protected and diabetic animals ( Fig. 2c-e ). CD8 T-cell proliferation was significantly suppressed in the presence of LPS-stimulated B cells (B LPS ) compared with unstimulated B cells (B US ) (p < 0.05; Fig. 2c-e ). Interestingly, no suppression by B cells from either protected or diabetic NOD mice was observed when the B cells were activated by other stimuli ( Fig. 2c-e ). Control CD8 T-cell proliferation (CD8 + DC alone) is shown in Supplementary Fig. 2a . Similarly, we observed reduced expression of CD44 ( Fig. 2f, g) and MIP1β, the early chemokine produced by activated CD8 T cells, in culture supernatants in the presence of B LPS (Fig. 2h ) . To confirm that CD8 T-cell proliferation was impaired in B LPS cultures and that this change was not due to increased CD8 T-cell death, we assessed CD8 T-cell viability and determined that there was no significant difference between cultures ( Supplementary Fig. 2b ).
To verify that the suppression mediated by B LPS was TLR4 dependent, we used B LPS from TLR4 -/mice in the culture system, and we observed no suppression of CD8 T-cell proliferation or activation ( Fig. 2i ), confirming that the LPS-mediated suppression was TLR4 dependent. To probe the direct effect of LPS-stimulated B cells on CD8 T cells, we stimulated G9Cα -/-CD8 T cells with plate-bound anti-CD3/28 antibodies and assessed CD8 T-cell proliferation in the presence of B cells with or without stimulation. In contrast to DC-stimulated T cells ( Fig. 2d ), anti-CD3/28 antibodystimulated CD8 T cells cultured with LPS-stimulated B cells (B LPS ) did not appear to be suppressed ( Fig. 2j ). Taken together, our results suggest that the regulation of antigen-specific CD8 T cells by LPS-activated B cells requires the presence of DCs, and importantly, B cells from diabetic mice also have the ability to impair CD8 T-cell responses, if the B cells are stimulated via TLR4.
IL-10 mediates CD8 T-cell suppression
To investigate the IL-10 contribution to CD8 T-cell suppression mediated by LPS-stimulated B cells, we measured the secreted IL-10 levels in culture supernatants of the experiments included in Fig. 2 . B LPS from both protected and diabetic mice had significantly increased IL-10 secretion compared with B US (Fig. 3a) . Interestingly, when LPS-stimulated B cells from aged B6 g7 transgenic mice (>35 weeks old) were used in our in vitro culture system, we neither observed significant CD8 T-cell suppression ( Supplementary Fig. 3a ) nor found significant IL-10 production ( Supplementary Fig. 3b ), demonstrating that IL-10 mediates suppression. Furthermore, the addition of LPS-stimulated NOD B cells had no obvious effect on the secretion of IL-6 (Supplementary Fig. 3c ), suggesting that reduced levels of IL-6 in protected NOD mice were not responsible for the suppression of CD8 T-cell proliferation.
To identify the contribution of IL-10 produced by DCs in our culture system, we analyzed the secreted IL-10 levels in cultures with or without DCs (Fig. 3b ). We found a significant increase in the amount of IL-10 secreted when B cells were added to DC + CD8 T-cell cultures, regardless of the B-cell source and whether the added B cells were unstimulated or stimulated. However, the greatest amount of secreted IL-10 was found in B LPS cultures. Cultures of CD8 T cells-DCs alone were found to have minimal secreted IL-10 (average 124 ± 25.4 pg/ml), suggesting that upon the addition of B cells, either the DCs or B cells, or both, contributed to the augmented IL-10 production. To further address this finding, B cells (B US , B LPS and B CD40 ) from protected, diabetic, and IL-10KO NOD mice were cultured with either BM-DCs from NOD.PI2tg mice or BM-DCs from IL-10KO NOD mice ( Fig. 3c ). IL-10 production in B-cell + DC cultures was dependent on the B cells being capable of producing IL-10, as only a small amount of IL-10 was observed when IL-10KO B cells were cultured with NOD.PI2tg BM-DCs ( Fig. 3c ). Analysis of the reduced amount of IL-10 produced in the IL-10KO cultures revealed no statistically significant difference between NOD.PI2tg BM-DCs cultured without B cells and those cultured with IL-10KO B cells ( Supplementary Fig. 4a ). Furthermore, equivalent amounts of IL-10 were produced when B cells from protected or diabetic NOD mice were cultured with IL-10KO BM-DCs ( Fig. 3c) , indicating that the IL-10 augmentation observed upon the addition of B cells is independent of IL-10 produced by BM-DCs.
As the secreted IL-10 contributed to the suppression of CD8 Tcell proliferation, we evaluated the effect of recombinant IL- 10 . Surprisingly, increasing concentrations of recombinant IL-10 alone had little effect on G9Cα -/-CD8 T-cell proliferation when the T cells were cultured with NOD.PI2tg DCs ( Supplementary Fig. 4b ).
Moreover, blocking the IL-10 receptor (anti-IL-10R antibody) also had little effect on either CD8 T-cell proliferation ( Supplementary  Fig. 4c , left) or CD44 expression in CD8 T cells ( Supplementary  Fig. 4c, right ). Yet, when B LPS cells were present in the CD8-DC culture system, adding anti-IL-10R antibody not only reduced the suppression of CD8 T-cell proliferation ( Fig. 3d ) but also promoted a significant increase in CD44 surface expression on CD8 T cells ( Fig. 3e ), compared to control. This finding was confirmed by using B cells from IL-10KO mice (Fig. 3d, e ). In keeping with published reports, 21, 22 IL-10 reduced the expression of costimulatory molecules on DCs to exert immunosuppression ( Supplementary  Fig. 4d ). We also found that the significant reduction in CD80 expression on mature DCs in B LPS cultures was reversed by the addition of the anti-IL-10R antibody or the use of B cells from IL-10KO mice (Fig. 3f ). However, CD86 expression on DCs was less affected by the addition of the anti-IL-10R antibody or the use of IL-10KO B cells ( Supplementary Fig. 4e ). Thus far, our results indicated that IL-10 produced by LPS-stimulated B cells downregulated CD80 expression on DCs and suppressed antigenspecific CD8 T cells.
Insulin-specific CD8 T-cell suppression is DC-B-cell contact dependent
To determine if cell contact is also required for B LPS -mediated CD8 Tcell suppression, we used a transwell culture system. CD8-DC cultures were either in contact with B cells (cont) or separated (trans) from B cells, which were unstimulated or stimulated with LPS (B LPS ) or anti-CD40 (B CD40 ) ( Fig. 4a ). Our results revealed that G9Cα -/-CD8 T-cell proliferation and the expression of CD44 on CD8 T cells were significantly suppressed when B LPS from either protected or diabetic NOD mice were in contact with the CD8 T cells and DCs. This suppression was significantly reduced when the B cells were separated from the CD8 T-cell-DC cultures (Trans) ( Fig. 4a, b) .
B-cell-DC contact synergises with cytokine production
Since we observed that CD8 T-cell suppression was mediated via both IL-10-and contact-dependent mechanisms, we sought to determine whether cytokine production was dependent on B cell-DC contact. We measured cytokine secretion when B cells were either in contact with mature NOD.PI2tg BM-DCs or cultured in transwells, in the presence (Fig. 4c , e) or absence of T cells (Fig. 4d, f) . First, we found that IFNγ production was unchanged by the addition of B cells from either protected or diabetic NOD mice, when B cells were not in direct contact (Trans) with CD8 T cells and DCs compared with when B cells were in contact (Cont) (Fig. 4c ). However, in the absence of CD8 T cells, B cells from diabetic NOD mice, in direct contact with DCs, induced more IFNγ production than B cells from protected NOD mice (p < 0.01), regardless of the type of stimulus (Fig. 4d ). Furthermore, IFNγ production was significantly increased when B cells were stimulated with anti-CD40 (B CD40 ) (protected, p < 0.05, diabetic, p < 0.001), and this effect was also contact dependent ( Fig. 4d) .
Second, we found increased IL-10 levels in both protected and diabetic B LPS cultures in the presence or absence of CD8 T cells, whereas we observed considerably less IL-10 expression in B LPS transwell cultures (Fig. 4e, f) . Interestingly, we observed that IL-10 production in B LPS cultures was greater in cultures of cells from diabetic NOD mice, than in those of cells from protected NOD mice, in the presence of CD8 T cells (Fig. 4e) . In contrast, in the absence of CD8 T cells, B LPS cultures of cells from protected NOD mice had the greatest levels of IL-10 ( Fig. 4f) . Notably, we observed no differences in IL-12p70 or IL-6 production when comparing B-cell contact and transwell cultures, indicating that these cytokines were not affected by direct B-cell contact (data not shown). Taken together, our data suggest that CD8 T-cell suppression is mediated via IL-10 secretion, which is dependent on direct contact between LPS-stimulated B cells and mature BM-DCs. B LPS condition mature BM-DCs We next investigated whether B cells induce tolerance in mature BM-DCs. First, we cocultured B cells with BM-DCs from NOD.PI2tg mice for 3 days. The B cells were then removed, and the conditioned BM-DCs were washed and cocultured with G9Cα -/-CD8 T cells for 3 days (scheme shown in Fig. 5a ), followed by assessment of CD8 T-cell proliferation (Fig. 5b) and activation (Fig. 5c ), as well as cytokine production in the DC-CD8 T-cell cultures (Fig. 5d ). Overall, CD8 T-cell proliferation (CFSE dilution) and activation (CD44 surface expression) were reduced when mature NOD.PI2tg BM-DCs were exposed to B cells, regardless of the stimulation; however, only B LPS , from either protected or diabetic NOD mice significantly suppressed insulin-specific CD8 T cells compared to the control(no B-cell exposure) ( Fig. 5b) . Following pre-exposure to B cells stimulated with LPS or anti-CD40, the BM-DCs in DC-CD8 T-cell cultures secreted IL-10 ( Fig. 5d, left) . However, only LPS-stimulated B cells reduced the secretion of proinflammatory cytokines, particularly IL-12p70 ( Fig. 5d, middle) and IL-6 ( Fig. 5d, right) , by mature BM-DCs.
B cells modulate the activation of mature conventional DCs
We have shown, thus far, that LPS-stimulated B cells suppress CD8 T-cell function, which is mediated via IL-10 and dependent on DC-B-cell contact. Considering the importance of B-cell-DC contact, we determined how B cells affect the activation of mature NOD.PI2tg BM-DCs, in the absence of T cells. We found that all B cells significantly increased the survival of DCs in cocultures ( Supplementary Fig. 5a ); however, B cells from protected NOD mice were more effective at enhancing DC survival compared with B cells from diabetic NOD mice ( Supplementary Fig. 5a ). In the protected NOD mouse cultures, B-cell contact was required for complete DC deactivation, as we found that MHC I, CD80, CD86, and CD69 expression levels were all significantly downregulated on mature BM-DCs cultured in contact (Cont) with LPS-stimulated B cells compared with those cultured with unstimulated B cells ( Fig. 6a, b) . B cells from protected NOD mice, when not in direct contact with DCs (Trans), were less effective in deactivating BM-DCs, with reduced downregulation of CD86 and CD69 expression ( Fig. 6a, b ). Our data suggest that B cells from protected mice suppress MHC I and CD80 expression on BM-DCs via soluble factors, whereas the suppression of CD86 and CD69 expression is mediated via contact-dependent mechanisms.
When investigating B cells from diabetic NOD mice, B LPS also downregulated the expression of all measured activation markers on DCs if cultured with direct contact (Cont) (Fig. 6a, b) . In contrast, when the same B cells were separated (Trans) from DCs, we observed minimal effects on mature BM-DCs. Interestingly, supernatants taken from B cells that had been stimulated in culture with the various stimuli (Sup), had no effect on the activation of BM-DCs compared with DC controls (dotted line, Fig. 6a, b ). However, in transwell cultures containing B LPS from protected mice, MHC I, CD80, and CD69 expression on the BM-DCs was still significantly reduced compared with the expression levels produced by exposure to B LPS supernatants, but this effect was not observed in the diabetic B-cell transwell cultures (Fig. 6a, b ). This finding suggests that B cells from protected mice can respond to BM-DCs and in turn deactivate the Notably, B cells from protected or diabetic NOD mice stimulated via TLR4 or anti-CD40 also significantly downregulated MHC II expression ( Supplementary Fig. 5b, c) , independent of cell contact. Collectively, these results reveal that the "deactivation" of mature conventional BM-DCs by B cells requires both direct contact and soluble mediators; MHC I, MHC II, and CD80 are more affected by soluble factors (most likely cytokines), whereas CD86 and CD69 are more dependent on direct cell contact. Furthermore, B cells that receive signaling via TLR4 relatively efficiently "deactivate" BM-DC, and B cells from protected NOD mice are the most effective.
B LPS cells induce tolerogenic CD45RB + CD11c low BM-DCs
To determine if LPS-stimulated B cells not only deactivate mature BM-DCs but also induce a tolerogenic DC population, we cultured B cells and NOD.PI2tg BM-DCs and evaluated different tolerogenic surface markers (Fig. 7) . We demonstrated that DCs cocultured with B LPS cells from protected or diabetic NOD mice exhibited significant induction of a subset of CD45RB + DCs compared with DCs cultured alone or with B US (Fig. 7a ). However, B LPS from protected NOD mice induced significantly more CD45RB + DCs compared with B LPS from diabetic NOD mice (p < 0.05). Interestingly, B cells from diabetic mice stimulated with anti-CD40 (B CD40 ) also induced a CD45RB + population. Furthermore, the induction of CD45RB + DCs was dependent on B-cell production of IL-10, as neither B LPS nor B CD40 from IL-10KO mice induced CD45RB expression on BM-DCs (Fig. 7a) . Similarly, the addition of B cells from B6 G7 mice, which have a reduced number of IL-10-producing B cells, had no effect on the induction of CD45RB expression on BM-DCs (data not shown).
This population of BM-DCs with CD45RB expression, a phenotype associated with regulatory DCs, had lower expression of CD11c compared with the CD45RB -BM-DC population (Fig. 7b, c) . 23, 24 Furthermore, significantly fewer CD45RB + BM-DCs had CD80 or CD86 expression ( Fig. 7b, c) compared with CD45RB -BM-DCs. No difference in the CD45RB + phenotype was observed between protected and diabetic cultures; therefore, the overall phenotype is shown (Fig. 7b, c) . We also investigated the expression of PD-L1 and ILT3 on BM-DCs with or without B-cell contact and did not find any obvious differences (data not shown), indicating that the tolerogenic DCs induced by B cells in this study did not function through the inhibitory markers PD-L1 and ILT3. 25, 26 
DISCUSSION
We have several novel findings in this study. First, we report that B cells from NOD mice that are naturally protected from diabetes have an increased frequency of IL-10-expressing B cells, while B cells from nonprotected diabetic NOD mice show an altered IL-10 profile (Fig. 8, parts 1, 2) . Second, we show that TLR4-activated B cells amplify their IL-10 production in response to contact with mature BM-DCs, inducing a tolerogenic DC state that can suppress pathogenic CD8 T cells (Fig. 8, part 3) . Third, B cells from diabetic NOD mice have a diminished response to BM-DCs (Fig. 8, part 4) ; however, they regain IL-10 production and the function of suppressing insulin-specific CD8 T cells in the presence of proinflammatory cytokines and TLR stimulation (Fig. 8, part 5) . Last, we show that B cells deactivate mature BM-DCs via both soluble mediators and cell contact-dependent mechanisms. IL-10-producing B cells (B10) restrain inflammatory responses, and it has been widely documented that B10 cells can negatively regulate autoimmune diseases. Furthermore, it is implied that IL-10-producing B cells are lost in patients with type 1 diabetes compared with healthy control individuals. 13 Notably, B10 cells can be induced through both adaptive immune (anti-CD40) signaling and innate TLR signaling, 16 which are regulated via different mechanisms, 2, 27, 28 under various inflammatory conditions. Our results reveal a loss of cytoplasmic IL-10 in nonprotected diabetic NOD mice, specifically upon stimulation with CD40. In line with this finding, compared with healthy control subjects, patients with systemic lupus erythematosus (SLE) have impaired CD19 + CD24 hi CD38 hi Breg populations that are refractory to CD40 stimulation. 29 This impairment is associated with a lack of STAT-3 phosphorylation after CD40 engagement and the expression of CD40 was not altered. 29 There was no difference in CD40 expression on splenic B cells between protected and diabetic mice in our study (data not shown) or in the studies of others. 13 The lack of an IL-10 response following anti-CD40 stimulation could be due to other factors. These other factors include retention of IL-10 by B cells from protected mice, trafficking out of the spleen of B cells that respond to CD40 stimulation, and destruction of B cells in vitro after stimulation (however, no difference was observed in B-cell viability) or in vivo by other cell types, such as FasL + CD5 + B cells. 30 Altogether, our current results support the concept that there is a strong association between CD40 stimulation and the immune regulation of autoimmune disease. 4, 31 Importantly, our study shows, for the first time, that the impaired IL-10 response by B cells in diabetic NOD mice can be restored upon activation via TLR4 or TLR9 signaling. Under these circumstances, the secretion of IL-10 by B cells in diabetic NOD mice was increased compared with that of B cells from protected mice stimulated with CPG, or to a lesser extent, LPS. Considering that we found that B cells from diabetic mice were more activated, it is possible that these cells are primed to secrete cytokines more rapidly. Although others have reported that LPS-stimulated B cells from very young NOD mice exert regulatory effects on type 1 diabetes via secreted TGFβ, 2 we did not detect any TGFβ secretion in our assays (data not shown). This disparity may be due to the differences in the ages of the mice studied.
In this study, we demonstrate that NOD B cells can deactivate mature BM-DCs via both soluble mediators and cell contactdependent mechanisms. TLR4-stimulated B cells produced more IL-10 and exhibited a stronger capacity to deactivate BM-DCs than unstimulated B cells; specifically, the expression of MHC I, MHC II, and CD80 on BM-DCs was clearly reduced. Furthermore, the expression of CD86 and CD69 was downregulated by direct Bcell-DC contact. Importantly, B cells from diabetic NOD mice stimulated via anti-CD40 were not as effective in deactivating DCs as B cells from protected NOD mice. This could be, in part, due to the increased secretion of IFNγ upon B-cell-DC contact in diabetic NOD mice. In addition, we found that BM-DCs exposed to LPSstimulated B cells produced reduced amounts of IL-12p70 and IL-6 but an increased amount of IL-10, in line with the B-cell-DC interactions noted previously. 32 B cells activated to produce IL-10 by Leishmania major infection induce suppression of IL-12 production by DCs. 33 Similarly, CpG-activated neonatal B cells are able to suppress IL-12 production by neonatal dendritic cells. 34 Direct B-cell-DC interactions have been shown using B-celldeficient (μMT -/-) mice, whose DCs produce higher levels of IL-12p70 than those from wild-type animals. 35 Furthermore, it is known that DCs cultured with IL-10 can shift from a Th1 pathway by reducing IL-12 secretion, 21 and IL-10 can also affect DC antigen presentation. 36 It is conceivable that the reduction in MHC II expression on BM-DCs induced by IL-10-producing B cells in our study could impact antigen presentation by DCs to CD4 T cells, leading to suboptimal CD4 T-cell activation.
It is clear that TLR4-activated NOD B cells operate directly on BM-DCs to inhibit CD8 T-cell activation. We found that B-cell-DC contact also amplified B-cell secretion of IL-10, which was exaggerated in the presence of IFNγ-producing CD8 T cells. Our finding is consistent with that of a previous study suggesting that inflammatory cytokines can increase IL-10 production by Breg cells. 37 However, we also found that IL-10 alone was not sufficient to inhibit BM-DC-induced CD8 T-cell proliferation, suggesting a contact-dependent change in BM-DCs upon initial engagement with B cells. Furthermore, whether this initial contact-dependent change is reciprocal and whether CD45RB hi CD11c low DCs have any reverse effects on B cells are not yet known.
In this study, we also demonstrated IL-10-dependent induction of CD45RB + CD11c low BM-DCs, a distinct subset of tolerogenic CD45RB hi CD11c low DCs, 38 which were induced most efficiently with LPS-stimulated B cells from protected NOD mice. A previous study suggests that a similar tolerogenic DC population produces IL-27 and promotes T-cell tolerance via IL-10. 24 Interestingly, this population can be induced with galectin-1, 24 which has recently been described to be required for regulatory B cell functions. 39 Whether this mechanism is involved in the induction of the CD45RB + CD11c low tolerogenic DC population by B cells in our study needs to be further investigated.
Our results are in line with findings on human B-cell-DC interactions, showing that human B cells influence the differentiation of DCs. [40] [41] [42] B cells activated by CD40 and TLR9 can also restrict Representative flow plots for CD11c, CD80, and CD86 expression in CD45RB + (solid line) and CD45RB -(dashed line) populations. c CD11c, CD80, and CD86 summary graphs for CD45RB + and CD45RBpopulations pooled from protected or diabetic NOD mice. The data are shown as the mean ± SEM. The data shown represent three independent experiments. *P < 0.05, **P < 0.01, and ***P < 0.001; two-way ANOVA monocytes from developing into mature DCs and reduce the expression of activation molecules and production of cytokines by DCs. 40 Similarly, B cells activated via BCR signaling can induce DC maturation, which then drives the differentiation of CD4 T cells into Th2 cells. 42 Again, this maturation is dependent on B-cell-DC contact and B-cell factors such as BAFFR (B-cell-activating factor receptor), TACI (transmembrane and calcium-modulating cyclophilin ligand interactor), and CD69. 42 It is clear that there is important cross-talk between B cells and DCs, and this is dependent on which signals B cells receive. 41 Our results suggest that the cross-talk between B cells and DCs is mutually modulated and both cell contact dependent and cell contact independent.
In summary, we have found that B cells play a novel role in the natural protection of NOD mice from diabetes. B cells from protected NOD mice produce high levels of IL-10 and suppress the activation of BM-DCs, which control pathogenic CD8 T cells. In contrast, B cells from nonprotected diabetic NOD mice have reduced IL-10 expression, especially upon activation with CD40, and weak suppressive function. Interestingly and importantly, if B cells from nonprotected diabetic mice are stimulated through innate immune signaling pathways, in particular the TLR4 (LPS) pathway, these B cells have the capacity to produce IL-10, and the immunosuppressive function is restored. This alteration of the suppressive B-cell function under innate immune activation or inflammatory conditions may contribute to the dysregulation or abnormalities in DC populations found in individuals with type 1 diabetes. 43 Thus, our study may point to a possible therapeutic target for future investigation.
METHODS
Mice NOD/Caj mice, originally from Yale University, were bred in-house at Cardiff University. G9Cα -/-NOD mice were bred in-house at Cardiff University as previously described. 20 NOD TLR4 -/mice were bred in-house at Yale University. NOD.PI2 tg mice, which have transgenic overexpression of PI2 driven by the MHC class II promotor, were kindly provided by Prof. L. Harrison and Dr. A. Lew. B6 g7 mice were bred in-house at Cardiff University. NOD.129P2 (Cg)-Il10tm1Cgn/DvsJ (IL-10KO) mice were bred in-house at Yale University. Mice were maintained at Cardiff or Yale University in specific pathogen-free isolators or scantainers. All animals received water and food ad libitum and were housed with a 12h dark/light cycle. Animal experiments were conducted in accordance with the United Kingdom Animals (Scientific Procedures) Act, 1986 and associated guidelines.
Diabetes incidence
Mice were monitored weekly for glycosuria (Bayer Diastix) beginning at 12 weeks of age and diagnosed as diabetic when blood glucose levels were >13.9 mmol/L. NOD mice that were 35 weeks of age or older, had never tested positive for glycosuria, and had blood glucose levels <13.9 mmol/L were considered to be protected from diabetes, as the incidence of diabetes after this age is very low.
Reagents
In vivo Mab anti-mouse IL-10R (CD210), In vivo Mab rat IgG1 isotype control, anti-CD3 (clone 2C11), and anti-CD28 (clone 37.51) 
Cell preparation
Bone marrow (BM-DCs) cells were flushed out from the hind leg bones (femur and tibia), cultured with granulocyte macrophage colony-stimulating factor (GM-CSF) at 1.5 ng/ml, and stimulated overnight with LPS (Sigma) at 1 μg/ml before the coculture system was set up. Whole splenocytes or freshly isolated splenic B cells, which were selected by using a B cell isolation kit (Miltenyi), were seeded at either 1 × 10 6 /ml in a 24-well plate (for phenotyping) or 5 × 10 6 cells/ml in a six-well plate (for cocultures) and either left unstimulated or stimulated with 5 μg/ml lipopolysaccharide (LPS), 5 μg/ml anti-CD40 (Bioexcell), or 0.5 μg/ml CPG (Eurofins MWG) for 24 h before harvesting for further assays. CD8 T cells were negatively selected with a CD8 T cell isolation kit (Miltenyi). The purity following all cell-sorting processes was >95%. blocking experiments, 10 μg/ml anti-IL-10R antibody or isotype control was added for the 3-day culture. NOD.PI2 tg BM-DCs (4 × 10 5 ) were also cultured with recombinant IL-10 (Miltenyi Biotech) alone, at increasing concentrations. Plate-bound anti-CD3/CD28 antibodies (0.1 μg/ml anti-CD3 antibody, 1 µg/ml anti-CD28 antibody) were used to coat a 48-well plate overnight at 4°C. The plate was washed with PBS before plating G9Cα -/-CD8 T cells labeled with CFDA-SE, and the cells were cultured with or without NOD B cells treated with different stimuli. After 3 days, the assays were analyzed by flow cytometry.
Flow cytometry
Single-cell suspensions were incubated with TruStain (antimouse CD16/32 antibodies [BioLegend]) for 10 min at 4°C, followed by incubation with fluorochrome-conjugated mAbs against cell surface markers for 30 min at 4°C. Multiparameter flow cytometry was carried out by using the following mAbs: CD8 PE594 (53-6.7), CD19 AF700 (6D5), CD11b APC or BV421 (M1/70), CD11c Pe-Cy7 (N418), MHC I PE (SF1-1.1), MHC II FITC (10-3-6), CD80 BV650 (16-10A1), CD86 Pe-Cy7 or AF700 (PO3), CD44 BV711 (IM7), PD-L1 APC (10F-962), OX-40L Pe-Cy7 (RM134), CD69 BV510 (H1-2F3), and CD45RB PerCPCy5.5 (C363-16.7) (all from BioLegend). APC-Cy7-(1D3) and PerCPCy5.5-conjugated (N418) anti-CD11c antibodies were purchased from eBioscience, and a BV786-conjugated BAFFR antibody (7H22-E16) was purchased from BD Biosciences. Cells were also stained with live/dead exclusion 605 (Invitrogen) or 780 (eBioscience). For intracellular cytokine analysis, splenocytes were either left unstimulated or stimulated for 24 h. Three hours before antibody staining, PMA (50 ng/ml), ionomycin (500 ng/ml), and monensin (3 µg/ml) (all from Sigma-Aldrich) were added to the cells. Fc receptors were blocked by using TruStain, and after extracellular staining, the cells were fixed by using a fixation/ permeabilization kit according to the manufacturer's instructions (BD Biosciences) and subsequently stained with antibodies specific for intracellular cytokines or appropriate isotype controls. Cells were acquired on an LSRFortessa (FACSDiva software), and analysis was performed by using FlowJo software (TreeStar).
Cytokine assays Supernatants were taken from cell culture assays at the 3-day endpoint to analyze IL-10, IL-12p70, MIP1β, IFNγ, and IL-6. Levels of the cytokines IL-10, IL-12p70, IFNγ, and IL-6 were measured by a Meso Scale Discovery (MSD) system, and the MIP1β level was measured by ELISA (R&D systems). MSD was performed according to the manufacturer's (Meso Scale Diagnostics, LLC) instructions and evaluated by using the MSD Sector Imager 6000. The MIP1β ELISA was run according to the manufacturer's instructions (R&D systems).
Statistical analysis
Statistical analysis was performed by using GraphPad Prism (GraphPad Software, San Diego, CA). Significance was determined by one-way ANOVA followed by Dunn's multiple comparison test or two-way ANOVA followed by the Bonferroni posttest for more than two variables, and a Mann-Whitney U test was performed to compare only two variables. Data were considered significant at p < 0.05.
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